Immunic, Inc.
IMUX
$1.12
-$0.03-2.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.01M | 4.36M | 4.49M | 5.15M | 4.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.63M | 25.73M | 22.81M | 23.88M | 23.38M |
| Operating Income | -25.63M | -25.73M | -22.81M | -23.88M | -23.38M |
| Income Before Tax | -25.18M | -24.37M | -21.38M | -29.58M | -21.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.18M | -24.37M | -21.38M | -29.58M | -21.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.18M | -24.37M | -21.38M | -29.58M | -21.57M |
| EBIT | -25.63M | -25.73M | -22.81M | -23.88M | -23.38M |
| EBITDA | -25.60M | -25.68M | -22.78M | -23.86M | -23.36M |
| EPS Basic | -0.25 | -0.24 | -0.21 | -0.30 | -0.48 |
| Normalized Basic EPS | -0.16 | -0.15 | -0.13 | -0.16 | -0.30 |
| EPS Diluted | -0.25 | -0.24 | -0.21 | -0.30 | -0.48 |
| Normalized Diluted EPS | -0.16 | -0.15 | -0.13 | -0.16 | -0.30 |
| Average Basic Shares Outstanding | 100.70M | 101.27M | 101.27M | 97.30M | 44.60M |
| Average Diluted Shares Outstanding | 100.70M | 101.27M | 101.27M | 97.30M | 44.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |